A theoretical study on the efficacy and mechanism of combined YAP-1 and PARP-1 inhibitors in the treatment of glioblastoma multiforme using peruvian maca Lepidium meyenii

Title : A theoretical study on the efficacy and mechanism of combined YAP-1 and PARP-1 inhibitors in the treatment of glioblastoma multiforme using peruvian maca Lepidium meyenii

Abstract:

Glioblastoma multiforme (GBM) is one of the most aggressive and treatment-resistant forms of brain cancer. Current therapeutic strategies, including surgery, chemotherapy, and radiotherapy, often fail due to the tumor’s ability to develop resistance. The proteins YAP-1 (Yes-associated protein 1) and PARP-1 (Poly-(ADP-ribose)–polymerase-1) have been implicated in this resistance, playing crucial roles in cell proliferation and DNA repair mechanisms, respectively. This study explored the inhibitory potential of natural compounds from Lepidium meyenii (Peruvian Maca) on the YAP-1 and PARP-1 protein systems to develop novel therapeutic strategies for GBM. By molecular dynamics simulations, we identified N-(3- Methoxybenzyl)-(9Z,12Z,15Z)- octadecatrienamide (DK5) as the most promising natural inhibitor for PARP- 1 and stearic acid (GK4) for YAP-1. Although synthetic inhibitors, such as Olaparib (ODK) for PARP-1 and Verteporfin (VER) for YAP-1, only VER was superior to the naturally occurring molecule and proved a promising alternative. In conclusion, natural compounds from Lepidium meyenii (Peruvian Maca) offer a potentially innovative approach to improve GBM treatment, complementing existing therapies with their inhibitory action on PARP-1 and YAP-1.

Biography:

Albert Gabriel Turpo-Peqqueña is a medical student at the Catholic University of Santa María, Arequipa, Perú, and a graduate in Biology from the National University of San Agustín. He has completed clinical and research internships in France, Sweden, and Brazil. His academic focus lies in neuro-oncology and neurosurgery, with a special interest in molecular mechanisms of brain tumors. Albert has received two national research awards for first place and has contributed to two peer-reviewed publications, aiming to integrate clinical practice with innovative therapeutic strategies in neuro-oncology.